Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

AUG 31 2022

Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T.

District Court ruling was favorable on ‘066 patent and unfavorable on ‘793 patent All patent claims asserted have been found to be either invalid or not infringed by District Court or U.S. Patent Trial and Appeal Board (PTAB) PTAB decision to invalidate all claims of ‘793 patent is not affected
AUG 22 2022

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C. , Aug. 22, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 7,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022

btn News